PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
Background: The evolution of therapeutic landscape of human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC) has led to an unprecedented outcome improvement, even if the optimal sequence strategy is still debated. To address this issue and to provide a picture of the advancement...
Guardado en:
Ejemplares similares
-
Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
por: Giacomo Barchiesi, et al.
Publicado: (2021) -
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
por: Evelina Miele, et al.
Publicado: (2009) -
Modelo del desamparo aprendido: aportes teóricos y clínicos a la depresión
por: Marchetti, Ana María
Publicado: (1983) -
Keratotic papules of palms and soles
por: Vincenzo Maione, et al.
Publicado: (2015) -
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
por: Laura Pizzuti, et al.
Publicado: (2021)